Compare LyondellBasell Industries NV (LYB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Repligen Corporation Common Stock — how do they compare? LyondellBasell Industries NV trades at $61.68 (market cap $19.39B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 4.6% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 88 Days and Repligen Corporation Common Stock for 0 Days on average.
| LYB | RGEN | |
|---|---|---|
Market Cap | $19.39B | $11.14B |
Volume | 3,160,509 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $194.57 |
52-Week Low | $42.28 | $102.87 |
Typical Hold Time | 88 Days | 0 Days |
Enterprise Value | $30.98B | $11.02B |
Dividend Yield | 4.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.17, up 2.96% today, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $745 million in 2025, with revenue declining to $30.15 billion, though recent quarters have beaten EPS estimates. Analyst sentiment is balanced with a 45% buy and 45% hold rating, and a consensus price target of $68.56 suggests modest upside. The dividend yield remains a key focus amid sector challenges.
The outlook for LYB hinges on earnings recovery and dividend sustainability. Opportunities include operational leverage and favorable market conditions, but risks involve persistent negative margins, high debt levels, and competitive pressures. The stock's performance will likely depend on reversing profitability trends and maintaining investor confidence through consistent dividend payments.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
